Nasdaq Divergence: Chips Rally on CPI Data as Amgen Sheds 6% Amgen (AMGN) shares plunged nearly 6% this week following a setback in an early-stage drug trial, a stark contrast to the semiconductor sector which led the Nasdaq Composite to weekly gains. The rally in chipmakers like Advanced Micro Devices (AMD) and Intel (INTC) came after the Consumer Price Index (CPI) report met analyst expectations, easing investor concerns about inflation. ## Background The market entered the week with institutional positioning cautious ahead of the inflation report. A CPI print that deviates from consensus can force the Federal Reserve to adjust its interest rate policy, which directly impacts company valuations. With the latest data showing inflation is not re-accelerating, traders priced in a lower probability of further rate hikes. This particularly benefits growth stocks, whose valuations are sensitive to the discount rate applied to their long-term projected earnings per share (EPS), or net profit allocated to each share of stock. Within the tech sector, semiconductor stocks have been standout performers, driven by demand for artificial intelligence applications. The Philadelphia Semiconductor Index (SOX) has reflected this optimism, though some analysts have questioned the sustainability of the rally and the high valuation multiples — the ratio of a company's stock price to its earnings. In biotech, Amgen had been viewed as a stable large-cap pharmaceutical company, but with significant potential tied to its pipeline. The negative trial data punctures that specific growth story. ## Why it matters This week's price action reveals a sharp divergence inside the Nasdaq. A favorable macro print (CPI) is lifting an entire sector sensitive to economic growth and interest rates, while a company-specific event is punishing another. The rally in semiconductors has a broad read-through for the health of enterprise tech spending and the ongoing buildout of AI infrastructure. The move puts pressure on investors who were underweight the chip sector or betting on a reversal of its strong year-to-date performance. Conversely, Amgen's decline is a reminder that even in a "risk-on" tape, idiosyncratic risk in biotech remains decisive. The sell-off hits investors who owned Amgen for its perceived pipeline strength in a high-growth area. It also benefits competitors in the obesity drug space. The divergence highlights a market that is not trading on a single theme, but is differentiating between secular growth stories like AI chips and clinical execution in biotech. ## What to watch The key question is whether the semiconductor rally has further momentum or if this was a short-term relief bounce. Watch the performance of the SOX index relative to the broader Nasdaq through mid-summer. By July 26, 2024, continued outperformance by chipmakers would signal sustained conviction in the AI theme, likely supported by strong guidance or new enterprise spending commitments. Conversely, a reversion where the SOX begins to lag, or announcements of softening demand for electronics, would suggest this week's strength was not durable and the sector is vulnerable to a pullback.